Nancy Helen Snyder

US Patent:

7820671, Oct 26, 2010

Filed:

Aug 31, 2001

Appl. No.:

10/344112

Inventors:

Robert Edward Babine - Carlsbad CA, US
Shu Hui Chen - Thousand Oaks CA, US
Ivan Collado - Madrid, ES
Cristina Garcia-Paredes - Madrid, ES
John Irvin Glass - Germantown MD, US
Deqi Guo - Carmel IN, US
Ling Jin - Indianapolis IN, US
Jason Eric Lamar - Indianapolis IN, US
Nancy June Snyder - Lizton IN, US
Xicheng David Sun - Broumfied CO, US
Mark Joseph Tebbe - Zionsville IN, US
Frantz Victor - Indianapolis IN, US
Yvonne Yee Mai Yip - Indianapolis IN, US
Robert B. Perni - Marlborough MA, US
Luc Farmer - Foxborough MA, US

Assignee:

Vertex Pharmaceuticals Incorporated - Cambridge MA

International Classification:

A61K 31/497
C07D 241/02

US Classification:

5142521, 544406

Abstract:

The present invention relates to peptidomimetic compounds useful as protease inhibitors, particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective processes to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient.